Matteo Della Porta: The final analysis of the COMMANDS trial comparing Luspatercept vs Epoetin alfa
Matteo Della Porta, Professor of Hematology at Humanitas University and shared a post on LinkedIn:
”Just published in Lancet Haematology the final analysis of the COMMANDS trial comparing Luspatercept vs. Epoetin alfa as first line treatment of patients with lower-risk Myelodysplastic Syndromes (MDS) and transfusion-dependent anemia.
Luspatercept represents a new standard of care for patients with transfusion-dependent, lower-risk MDS. Significantly more patients had red blood cell transfusion independence and hematological improvement with Luspatercept than with Epoetin alfa, with benefits observed across patient subgroups.”
Authors: Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Richard Pilot, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Thomas Prebet, Yinzhi Lai, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Pierre Fenaux, Uwe Platzbecker.
Source: Matteo Della Porta/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023